TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Collagenase Option for Reduction of Dupuytren's Contracture in Japan

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At least 20 years old when written informed consent is obtained.~* Having a diagnosis of Dupuytren's contracture and flexion contracture due to palpable cord in at least 1 non-thumb finger (20° to 100° in MP joint and 20° to 80° in PIP joint).~* Positive tabletop test result (i.e., cannot simultaneously place affected finger and palm on a table).~* Voluntary written informed consent is obtained.~Exclusion Criteria:~Patients meeting any of the following criteria will be excluded:~* Is pregnant, may be pregnant, wishes to become or could become pregnant during the study (i.e., unless acceptable contraception is used, the patient has been sterilized, or the patient is postmenopausal \[no menstrual period for at least 12 months without any other medical cause\]), or is breastfeeding.~* Has a coexisting chronic disease of the hand that could impact assessment (muscular disease, neurological disease, neuromuscular disease).~* Has received another investigational product 30 or fewer days before first injection of the investigational product.~* Has undergone aponeurectomy, aponeurotomy, needle aponeurotomy/fasciotomy, verapamil/interferon injection, or another Dupuytren's Contracture treatment of the primary joint 90 or fewer days before first injection of the investigational product.~* Is allergic to collagenase or any of the excipients of AK160.~* Has taken tetracycline derivative such as minocycline and doxycycline 14 or fewer days before first injection of the investigational product.~* Has received a collagenase product 30 or fewer days before first injection of the investigational product.~* Is currently taking or has taken, 7 or fewer days before first injection of the investigational product, an anticoagulant or antiplatelet drug (other than ≤150 mg/day of aspirin).~* Has suffered a recent stroke, hemorrhage, or other disease affecting the hands.~* Has a serious disease unsuited for the study.~* Receiving treatment for a malignancy.~* History of drug or alcohol addiction within the past 5 years or history of drug or alcohol abuse within the past year.~* Has received previously the investigational product (AK160, AA4500, XIAFLEX®, or XIAPEX®).~* Otherwise found ineligible as a subject by the investigator.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AK160 0.58 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has a clinical diagnosis of stable plaque psoriasis~* Subject has an ODS score for the Treatment Area of 3 or 4 at study start~Exclusion Criteria:~* Subject has spontaneously improving or rapidly deteriorating plaque psoriasis.~* Subject has guttate, pustular, erythrodermic or other non-plaque forms of psoriasis.~* Subject has used any phototherapy, photo-chemotherapy or systemic corticosteroid therapy within 30 days prior to study start~* Subject has used any systemic methotrexate, retinoids, cyclosporine or analogous products within 90 days prior to study start~* Subject has used any systemic biologic therapy for the treatment of psoriasis within 5 half-lives of the biologic prior to study start~* Subject had prolonged exposure to natural or artificial sources of ultraviolet radiation within 30 days prior to study start~* Subject has used topical body (excluding the scalp) psoriasis therapy including coal tar, anthralin, steroids, retinoids, vitamin D analogs (e.g., Dovonex®) within 14 days prior to study start~* Subject has used emollients/moisturizers on areas to be treated within four hours prior to clinical evaluation at study start~* Subject is currently using lithium or Plaquenil (hydroxychloroquine)~* Subject is currently using a beta-blocking medication (e.g., propranolol) or ACE (e.g., lisinopril) inhibitor at a dose that has not been stabilized~* Subject is pregnant, lactating, or is planning to become pregnant during the study~* Subject is currently enrolled in an investigational drug or device study~* Subject has used an investigational drug or investigational device treatment within 30 days prior to study start~* Subject has been previously enrolled in this study and treated with a test article

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 122-0551 (Type: EXPERIMENTAL): None
- Vehicle (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed IBS diagnosis per Rome II criteria for diagnosis of IBS.~* Colonoscopy within 2 years as part of IBS diagnostic evaluation.~* Has active symptoms of non-constipation IBS at baseline as measured by average daily scores for abdominal pain/discomfort, bloating, and stool consistency.~Exclusion Criteria:~* Symptoms of constipation.~* History of other gastrointestinal diseases.~* Type 1 or 2 diabetes.~* Lactose intolerance not controlled by lactose-free diet.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Subjects received placebo tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
- Rifaximin (Type: EXPERIMENTAL): Subjects received rifaximin 550 mg tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria~* Males and females, aged 2 to \<18 years~* Hepatitis B surface antigen-positive~* Detectable hepatitis B e (HBe) antigen, and no detectable anti-HBe antibodies~* Alanine aminotransferase (ALT) 1.5 to \<10 times the upper limit of normal at screening and within 8 to 24 weeks prior to screening~* Evidence of the presence of hepatitis B virus DNA at least 4 weeks before screening and \>100,000 copies/mL at screening~Key Exclusion Criteria~* Any prior therapy with entecavir~* At least 12 weeks of prior therapy with any nucleoside or nucleotide antiviral agent~* Therapy with interferon alpha, thymosin alpha, or nucleototide antiviral agents within 24 weeks of screening~* Coinfection with HIV, hepatitis C virus, or hepatitis D virus~* Decompensated liver disease~* Liver transplant recipients~* Other forms of acute and chronic conditions which may cause increased ALT levels~* Children who were breastfed while their mothers received lamivudine or whose mothers received lamivudine during pregnancy

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Entecavir (Type: ACTIVE_COMPARATOR): Participants received entecavir, 0.015 mg/kg up to 0.5 mg, once daily, for 96 to 144 weeks, depending on response
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo, 0 mg, once daily, for 48 to 96 weeks, depending on response

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Structured Treatment of Osteoarthritis of the Knee With or Without Total Knee Replacement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Knee-OA detected by x-ray (Kellgren \& Lawrence grade 2 or greater)~* Considered a candidate for TKR by the orthopedic surgeon.~* The participant is \> 18 years of age.~* The participant can provide relevant and adequate, informed consent.~Exclusion Criteria:~* Bilateral simultaneous TKR~* Revision of prior TKR, unicompartmental knee arthroplasty or high tibial osteotomy~* Rheumatoid arthritis~* Mean VAS \> 60mm on a 0-100mm scale~* Investigator considers that the mental condition of the participant does not allow participation.~* The participant must not be pregnant or plan pregnancy during the study.~* Inability to comply with the protocol;.~* Inadequacy in written and spoken Danish.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MEDIC (Type: ACTIVE_COMPARATOR): Medicine, Exercise, Diet, Insole and Cognitive/patient education (MEDIC) for three months.
- MEDIC + TKR (Type: ACTIVE_COMPARATOR): Medicine, Exercise, Diet, Insole and Cognitive/patient education (MEDIC) for three months after a total knee replacement.
- Observational Cohort (Type: ACTIVE_COMPARATOR): If the patient can be included, but doesn't want to participate in the randomization, the patient is offered to enter into a prospective observational cohort with the same endpoints and the same follow-up as in the randomized study. The participant can then, in consultation with his/her physician, choose whether they would like MEDIC-treatment or TKR in combination with MEDIC-treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or pathologically confirmed diagnosis of epithelial carcinoma of the ovary.~* Platinum resistant ovarian cancer (defined as relapsing within 6 months after the last administration of platinum-based chemotherapy) OR platinum refractory ovarian cancer (defined as progressing while on a platinum-based chemotherapy)~* At least treated with one line of platinum-based chemotherapy~* Female, age ≥18 years and ≤70 years, signed informed consent.~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2~* Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 version~* Patients must have a life expectancy of at least 3 months.~* Patients must have adequate organ function as defined by the following criteria:~  * White blood cell count ≥ 3 x 10\^9/L, Absolute neutrophil count (ANC) (≥ 1.5 x 10\^9/L), Hemoglobin of ≥ 80 g/L, Platelets ≥ 70 x 10\^9/L~ * Total bilirubin ≤ 1 x upper limit of normal (ULN), AST and ALT ≤ 2 x ULN~ * Serum creatinine ≤ 1 x ULN~Exclusion Criteria:~* Had prior exposure to apatinib or has known allegies to any of the excipients.~* History of myocardial infarction, or unstable angina, or New York Heart Association (NYHA) Grade III-IV within 6 months prior to Day 1.~* Patients with QT interval prolongation~* Serious, non-healing wound, active ulcer, bowel obstruction.~* History of abdominal fistula or gastrointestinal perforation within 28 days prior to Day 1~* Evidence of bleeding diathesis or coagulopathy~* Inadequately controlled hypertension~* Major surgical procedure within 28 days prior to Day 1~* Symptomatic central nervous system (CNS) metastasis

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Apatinib + Etoposide (Type: EXPERIMENTAL): Apatinib 500mg daily, po, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.~Etoposide 50mg daily, po, day 1 to day 14, repeat every 21 days for 6 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Methadone in Post-Herpetic Neuralgia Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with chronic (\>6 months) symptomatic PHN~* with visual analogical scale \>40/100mm~* use of first and second line drugs (tricyclic antidepressants, venlafaxine and gabapentinoids)~Exclusion Criteria:~* Don't full the criteria above

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Methadone (Type: EXPERIMENTAL): in this arm patients will take methadone 5mg.
- Placebo (Type: EXPERIMENTAL): in this arm patients will take placebo pills.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Drug Use Investigation of ENBREL for Post-marketing Surveillance (PMS) for RA and PsA

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~Rheumatoid Arthritis~* Adults: Treatment of active rheumatoid arthritis (RA) in adults when the response to disease-modifying antirhematic drugs (DMARDs), including MTX, has been inadequate~* Children: Treatment of active polyarticular-course chronic active rheumatoid arthritis in children aged 4 to 17 years who have had an inadequate response to, or whom have proved intolerant of, MTX~Psoriatic Arthritis~- Active and progressive psoriatic arthritis (PsA) in adults who do not respond adequately to previous DMARDs~Exclusion Criteria~* Patients to whom Enbrel is contraindicated as per the local labeling~* Patients with known hypersensitivity to Enbrel or any component of the product~* Patients with sepsis or risk of sepsis~* Patients with active infections including chronic or localized infections such as tuberculosis. (Treatment of Enbrel should not be initiated.)

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Post-marketing Surveillance to Assess the Safety of Boostrix Vaccine Given According to Prescribing Information in Korea

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Written or signed informed consent obtained from the subject/ subject's parent(s)/Legally Acceptable Representative(s) of the child. Korean male or female subjects who were recently vaccinated or eligible to receive Boostrix according to the locally approved Prescribing Information.~Exclusion Criteria:~* Those who are not eligible for vaccination according to the local Prescribing Information.~* Child in care.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Boostrix Group (Type: None): Pre-adolescents (aged (≥10 years to ˂12 years), adolescents (aged ≥12 to ˂19 years), adults (aged 19 to 64 years) and elderly (≥ 65) who received Boostrix as a part of routine practice at a private clinic or hospital in Korea.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented history of hypertension~* Triglycerides of 120-400 mg/mL~* LDLc levels not requiring lipid lowering medication.~Exclusion Criteria:~* Has known contraindication to alpha- or beta-blocker therapy.~* Has taken any non-ocular beta-blockers within three months before screening.~* Has Type I or II diabetes.~* Taking lipid lowering medications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Carvedilol Phosphate modified release formulation (Type: EXPERIMENTAL): None
- metoprolol succinate (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: S. Endotoxin, Inflammatory Mediators and MRS Before and After Treatment in MHE

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of Cirrhosis (Age 15 yr -70 yr )~Exclusion Criteria:~* Recent history of gastrointestinal bleed in last 6 weeks~* Active ongoing infection~* Creatinine \>1.5mg%~* Electrolyte impairment. (S. Sodium \< 130 meq/L, S. Potassium 3.5 meq/L or \>5.0meq/L)~* H/O use of psychotropic drugs in last 6 weeks~* Recent alcohol use (\< 6 week )~* H/O TIPS or shunt surgery.~* Hepatocellular Carcinoma~* Severe comorbidity as Congestive Heart Failure, Pulmonary disease, Neurological and Psychiatric problems impairing quality of life~* Poor vision precluding neuropsychological assessment

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Lactulose (Type: PLACEBO_COMPARATOR): Group L receives lactulose Group NL receives placebo
- Placebo (Type: PLACEBO_COMPARATOR): Group NL receives placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Convalescent Plasma in COVID-19 Elderly Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Elderly patients (\> 65 years old) with SARS-CoV-2 RT-PCR positivity on nasal swab or score higher than 5 with the following characteristics:~  * New onset or worsening of recently onset respiratory symptoms (\<10 days);~ * Radiological imaging (CT, X-ray, Ultrasound) of bilateral pulmonary opacities not fully explained by pleural effusion, pulmonary or lobar atelectasis, pulmonary nodules;~ * Respiratory failure (SpO2 \<95%) not fully explained by heart failure or water overload (after excluding hydrostatic causes of edema in the absence of risk factors by objective assessment, for example ultrasound);~* Patients who have signed informed consent.~Exclusion Criteria:~* New onset or worsening of respiratory symptoms that began more than 10 days ago;~* Patients with proven hypersensitivity or allergic reaction to plasma, blood products or immunoglobulins;~* Manifest desire not to be included in the research protocol.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- convalescent plasma (Type: EXPERIMENTAL): Cohort of elderly patients treated with convalescent plasma

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has 3 or more primary protease inhibitor mutations~* documented genotypic evidence of resistance to currently available NNRTIs (non-nucleoside reverse transcriptase inhibitors) by having at least 1 NNRTI resistance-associated mutation~* on a stable antiretroviral therapy for at least 8 weeks~* plasma viral load at screening visit \> 5000 HIV-1 RNA copies/mL.~Exclusion Criteria:~* Active AIDS defining illnesses (except for stable, cutaneous Kaposi's Sarcoma or wasting syndrome)~* Any grade 3 or grade 4 toxicity according to the DAIDS grading scale~* Use of disallowed concurrent therapy~* Any active clinically significant disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 001 (Type: ACTIVE_COMPARATOR): TMC125 2 x 100 mg tablets b.i.d. / 96 weeks
- 002 (Type: PLACEBO_COMPARATOR): Placebo 2 tablets b.i.d. / 96 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete